Laura Bukavina: NTACT residual disease test presented by Phillip Abbosh

Laura Bukavina, Urologic Oncologist at Cleveland Clinic, shared on X:

“The NTACT residual disease test, eloquently presented by Phillip Abbosh published in JCO Precision Oncology. Remarkably, over 50% of patients without visible residual disease had positive mutations, indicative of field cancerization—mutations present in adjacent normal tissue WITHOUT cancer. NTACT demonstrated 91% sensitivity and 82% accuracy.”

Read further.
Source: Laura Bukavina/X